Business Description
Apollon Formularies PLC
ISIN : IM00B3VVCM89
Description
Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.53 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 3.77 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 39.9 | |||||
| 3-Year EPS without NRI Growth Rate | 47.7 | |||||
| 3-Year FCF Growth Rate | 37.9 | |||||
| 3-Year Book Growth Rate | -67.8 |
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.6 | |||||
| Quick Ratio | 0.6 | |||||
| Cash Ratio | 0.03 | |||||
| Days Sales Outstanding | 5026.35 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -260.8 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -839.58 | |||||
| Net Margin % | -1591.67 | |||||
| ROE % | -29.66 | |||||
| ROA % | -20.07 | |||||
| ROIC % | -13.71 | |||||
| 3-Year ROIIC % | -86.71 | |||||
| ROC (Joel Greenblatt) % | -235.21 | |||||
| ROCE % | -15.64 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.03 | |||||
| EV-to-EBIT | -2.66 | |||||
| EV-to-EBITDA | -2.66 | |||||
| EV-to-Revenue | 22.33 | |||||
| EV-to-FCF | -34.58 | |||||
| Earnings Yield (Greenblatt) % | -37.59 | |||||
| FCF Yield % | -2.76 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Apollon Formularies PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil £) | |||
| EPS (TTM) (£) | - | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (£) | - | ||
| 20-Day SMA (£) | - | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (£) | 0 - 0.01 | ||
| Shares Outstanding (Mil) | 1,381 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Apollon Formularies PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Apollon Formularies PLC Stock Events
| Event | Date | Price (£) | ||
|---|---|---|---|---|
| No Event Data | ||||
Apollon Formularies PLC Frequently Asked Questions
What is Apollon Formularies PLC(LSE:3DR)'s stock price today?
The current price of LSE:3DR is £0.00. The 52 week high of LSE:3DR is £0.01 and 52 week low is £0.00.
When is next earnings date of Apollon Formularies PLC(LSE:3DR)?
The next earnings date of Apollon Formularies PLC(LSE:3DR) is .
Does Apollon Formularies PLC(LSE:3DR) pay dividends? If so, how much?
Apollon Formularies PLC(LSE:3DR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers